Kenneth Strauss
Diabetes is now a top public health challenge, with, according to the World Health Organization and International Diabetes Federation, the world “facing a growing diabetes epidemic of potentially devastating proportions” . In 2013, it was recorded that 382 million people in the world have diabetes and this figure is set to rise to 592 million by 2035. In addition, the number of people with type 2 diabetes is increasing in nearly every country (IDF, 2013) and as people are diagnosed at an earlier age, yet are living longer, there is an increasing likelihood that they will need to use injectable therapies to control their condition .It is well established that improving glycaemic control reduces the risk of developing long term complications. In the longer term, poor glycaemic control can increase the risk of complications including kidney failure, blindness and limb amputation, all of which have a devastating impact for the individual.
